Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.
Bravo, J.P.K., Dangerfield, T.L., Taylor, D.W., Johnson, K.A.(2021) Mol Cell 81: 1548-1552.e4
- PubMed: 33631104 
- DOI: https://doi.org/10.1016/j.molcel.2021.01.035
- Primary Citation of Related Structures:  
7L1F - PubMed Abstract: 
Remdesivir is a nucleoside analog approved by the US FDA for treatment of COVID-19. Here, we present a 3.9-Å-resolution cryo-EM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of 3 copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of 3 bases following RMP, resulting in delayed chain termination, which can guide the rational design of improved antiviral drugs.
Organizational Affiliation: 
Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.